Three kinds of rash in the documents
Saxenda® is injected every day, so the skin at injection sites is exposed far more often than with a weekly medicine. The label lists injection-site reactions as a group and footnotes the most common ones. Separately, it records rash as a general reaction in teenagers, hives as an allergic reaction, and rash among post-approval allergy reports. [1] The EU and Canadian documents divide things in a similar way. [2][3]
| Entry | Saxenda® | Placebo | Source |
|---|---|---|---|
| Injection-site reactions, adults (all types) | 13.9% | 10.5% | US Table 2 [1] |
| Injection-site redness / itching / rash, adults | 1%–2.5% each | — | US Table 2, footnote [1] |
| Injection-site rash, adults | 1.1% (36 of 3,384) | 0.1% (2 of 1,941) | Canadian Table 3 [3] |
| Injection-site itching, adults | 1.3% (43) | 0.2% (4) | Canadian Table 3 [3] |
| Rash, ages 12–17 | 3.2% | 0% | US Table 3 [1] |
| Rash, adults | Common (≥1/100 to <1/10) | — | EU Table 4 [2] |
| Urticaria (hives), adults | 0.7% | 0.5% | US section 6.1 [1]; EU: uncommon [2] |
Reactions where the needle goes in
Injection-site reactions were reported by 13.9% of adults on Saxenda® and 10.5% on placebo, which also involved daily injections. [1] The EU and Canadian documents describe them as usually mild and short-lived, with most fading while treatment continued. [2][3]
Antibodies to liraglutide developed in 2.8% of adults tested, and the label notes that their presence may be linked with more injection-site reactions; these were usually mild and settled without stopping. [1] A different skin problem, cutaneous amyloidosis, can cause lumps under the skin at repeatedly used sites, which is why the label asks you to rotate injection sites within the same region. [1][2]
Rash elsewhere on the body
A rash away from the injection site is a separate entry. The EU summary classes rash as common, and its package leaflet lists rash among common effects and “allergic reactions including skin rash” as uncommon. [2] The US adolescent table records rash in 4 of 125 teens on Saxenda® and none of 126 on placebo; small numbers, but a clear difference. [1]
After approval, rash and itching were reported as allergic reactions to liraglutide, without a frequency. [1][3] The Canadian composite count puts allergy-type events at 2.0% on Saxenda® and 2.4% on placebo, so in the trials allergy overall was not more frequent on the medicine. [3]
When the skin signals a serious allergy
Serious hypersensitivity, including anaphylaxis and angioedema (deep swelling of the face, lips, tongue or throat), has been reported with Saxenda®. The label tells anyone with a serious reaction to stop the medicine and seek medical help promptly, and it lists a previous serious reaction to liraglutide as a reason not to use it. [1] The EU summary places anaphylactic reactions in the rare band. [2]
MedlinePlus explains that anaphylaxis develops within seconds to minutes and can combine hives and itching with trouble breathing or swallowing, swelling of the face or tongue, and dizziness; it is an emergency. [8] The Saxenda® Medication Guide lists a severe rash or itching among the signs of a serious allergic reaction. [1]
What drug-safety databases show
An analysis of US adverse event reports from 2018 to 2024 compared skin reactions such as rash, itching, hives, hair loss and angioedema across four GLP-1 medicines. Skin reactions were proportionally less common than with DPP-4 inhibitors, another diabetes drug class, and liraglutide showed lower odds of a skin report than the reference medicine. [4] A European database study counted hypersensitivity in 0.73% and angioedema in 0.19% of liraglutide reports. [5] Neither kind of study can show cause or true frequency.
Everyday triggers, and gentle skin care
MedlinePlus lists many everyday causes of rashes: contact with soaps, detergents, cosmetics, latex or plants; eczema; psoriasis; infections such as shingles or impetigo; insect bites; and medicines. [6] Hives are commonly triggered by foods, drugs, infections or stress. [7]
For simple rashes, MedlinePlus suggests gentle cleansing with warm water, patting dry, avoiding scrubbing and stopping recently added skin products. [6] It advises contacting your provider about a rash when you are taking a new medicine, and not stopping or changing medicines without speaking to them. [6] Ask your pharmacist before using any cream or antihistamine, since the Medication Guide asks you to report all medicines you take. [1]
Saxenda® is a registered trademark of Novo Nordisk A/S. PepLabo is not affiliated with or endorsed by Novo Nordisk.
When to get help
| Sign | Who to contact | How fast | Source |
|---|---|---|---|
| Swelling of the face or throat, struggling to breathe or swallow, a very fast heartbeat or feeling faint | Emergency services (911 / 112); stop Saxenda® | Emergency | Medication Guide [1]; MedlinePlus [8] |
| Severe rash or itching spreading over the body | Stop Saxenda® and get medical help right away | Emergency | Medication Guide [1] |
| Red streaks, swelling or very tender skin around an injection site, or a rash with fever | Your prescriber | Today | MedlinePlus [6] |
| A new rash since starting Saxenda®, or a teenager with a rash on Saxenda® | Your prescriber | At your next appointment | MedlinePlus [6]; label [1] |
| Lumps that stay under the skin where you inject | Your prescriber or pharmacist | At your next appointment | Label [1]; EU leaflet [2] |
